Rexis Biotech has announced a strategic partnership with Happy Valley, a premium cannabis company based in Massachusetts. Happy Valley will leverage Rexis’ Fused Polymorph Nano Fiber technology to power its edible and drink products. The technology produces a water-soluble powder, providing a true rapid delivery system for customers. The partnership is expected to expand product offerings and drive revenue for both companies. Rexis is a leader in developing Hydrophobic Molecule Delivery systems, which are used to sustain strong sales models with pharmaceutical licensees, consumer packaged goods manufacturers, and clinical research teams.
Rexis Biotech Expands into Legal Cannabis Markets with Partnership
REXIS has revealed a long-term partnership with Happy Valley, a cannabis retailer based in Massachusetts. The strategic collaboration allows Rexis to broaden its growth and continue expansion into the legal cannabis markets. The announcement was made on March 22, 2023, and marks a significant milestone for the biotech company.
Rexis Biotech Partners with Happy Valley to Expand into Legal Cannabis Markets
Rexis Biotech Inc. (“REXIS”) has announced its continued expansion into the legal cannabis markets through a strategic partnership with Happy Valley, Inc. (“Happy Valley”), a full-service premium cannabis company based in Massachusetts. In 2022, Happy Valley was voted the #1 Massachusetts cannabis retailer by customers and independent industry experts. The partnership will allow Rexis to broaden its growth in the legal cannabis industry, while Happy Valley will leverage Rexis’ Fused Polymorph Nano Fiber technology to power its edible and drink products. This technology produces a water-soluble powder, offering a true rapid delivery system for customers. Happy Valley’s adoption of Rexis’ technology has already resulted in two first-place finishes for its gummi and drink mix formulations at the High Times Cannabis Cup in Massachusetts. The partnership between Rexis and Happy Valley is expected to expand product offerings and drive revenue for both companies.
Rexis Biotech Disclaimer and Contact Information
Please note that the statements in this press release have not been evaluated by the Food and Drug Administration, and products or ingredients are not intended to diagnose, treat, cure or prevent any disease. For more information about Rexis Biotech and its products, please visit their website at www.rexissystems.com. For any inquiries, please contact Ryan Erving at REXIS BIOTECH at extension 4036061498 or email via the provided link.
Don’t miss interesting posts on Famousbio
